All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Zinaida Perić, University of Rijeka, Rijeka, HR, shared her thoughts on patient eligibility, treatment optimization, and follow-up after treatment with ECP for cGvHD. She also discussed a case report of a patient with steroid-refractory (SR)-cGvHD, plus retrospective (Table 1) and prospective data on the use of ECP in cGvHD. In addition, she shared the Nordic ECP Quality Group treatment guidelines for SR-cGvHD.
Table 1. Retrospective data of ECP in SR-cGvHD*
ECP, extracorporeal photopheresis; SR-cGvHD, steroid-resistant chronic graft-versus-host disease.
*Data from Nygaard et al.1
Figure 1. Treatment guidelines proposed by the Nordic ECP Quality Group*
cGvHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; MR, minimal response; mixR, mixed response; NC, no change; PR, partial response; SR, steroid-refractory.
*Adapted from Lee et al.2
Listen to this presentation as a podcast here:
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
This symposium closed with a panel Q&A session with live audience participation, where our panelists discussed their perspectives on donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops.
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox